Page last updated: 2024-10-25

ciglitazone and Breast Neoplasms

ciglitazone has been researched along with Breast Neoplasms in 13 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
"The obesity hormone leptin has been implicated in breast cancer development."7.79Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. ( Amodeo, V; Bazan, V; Caruso, S; Cicero, G; Contaldo, C; Corsini, LR; Fanale, D; Fiorio, E; Insalaco, L; Lo Re, G; Mercanti, A; Russo, A; Surmacz, E; Terrasi, M, 2013)
"In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and ciglitazone on cyclin D1 repression."7.73Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. ( Brueggemeier, RW; Chen, CS; Chen, KF; Huang, JW; Kulp, SK; Shapiro, CL; Shiau, CW; Yang, YT, 2005)
"Thus, PPARgamma-induced inhibition of breast cancer cell growth is due, in part, to proteasome-dependent degradation of cyclin D1 (and ER alpha), and this pathway may be important for other cancer cell lines."5.32Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. ( Burghardt, R; Qin, C; Safe, S; Smith, R; Stewart, J; Wormke, M, 2003)
"The obesity hormone leptin has been implicated in breast cancer development."3.79Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. ( Amodeo, V; Bazan, V; Caruso, S; Cicero, G; Contaldo, C; Corsini, LR; Fanale, D; Fiorio, E; Insalaco, L; Lo Re, G; Mercanti, A; Russo, A; Surmacz, E; Terrasi, M, 2013)
"In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and ciglitazone on cyclin D1 repression."3.73Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. ( Brueggemeier, RW; Chen, CS; Chen, KF; Huang, JW; Kulp, SK; Shapiro, CL; Shiau, CW; Yang, YT, 2005)
"The PPAR-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone, and the PPAR-alpha ligand, WY-14643, were examined for their effects on proliferation and apoptosis of A375 melanoma, DU145 and PC3 prostate cancer, and MB-MDA-231 breast cancer."3.73PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. ( Liu, H; Meadows, GG; Núñez, NP, 2006)
"Doxorubicin is effective against breast cancer, but its major side effect is cardiotoxicity."1.39Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms. ( Arif, IS; Boateng, SY; Greco, F; Hooper, CL; Williams, AC, 2013)
"We used the common model of human breast cancer MCF-7 and examined the ability of MEHP and MBP to activate human PPARs in this system."1.33Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. ( Cabot, PJ; Davis, B; Monteith, GR; Roberts-Thomson, SJ; Robinson, JA; Venkata, NG, 2006)
"Thus, PPARgamma-induced inhibition of breast cancer cell growth is due, in part, to proteasome-dependent degradation of cyclin D1 (and ER alpha), and this pathway may be important for other cancer cell lines."1.32Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. ( Burghardt, R; Qin, C; Safe, S; Smith, R; Stewart, J; Wormke, M, 2003)
"Treatment of MDA-MB-231 breast cancer cells with NS-398 (a COX-2 inhibitor) or ciglitazone (CGZ, a PPARgamma-ligand) significantly inhibited cell proliferation and markedly increased apoptotic rates."1.32Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. ( Badawi, AF; Badr, MZ; Michael, MS, 2003)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's9 (69.23)29.6817
2010's3 (23.08)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mora, FD1
Jones, DK1
Desai, PV1
Patny, A1
Avery, MA1
Feller, DR1
Smillie, T1
Zhou, YD1
Nagle, DG1
Arif, IS1
Hooper, CL1
Greco, F1
Williams, AC1
Boateng, SY1
Davies, GF1
Ross, AR1
Arnason, TG1
Juurlink, BH1
Harkness, TA1
Terrasi, M1
Bazan, V1
Caruso, S1
Insalaco, L1
Amodeo, V1
Fanale, D1
Corsini, LR1
Contaldo, C1
Mercanti, A1
Fiorio, E1
Lo Re, G1
Cicero, G1
Surmacz, E1
Russo, A1
Qin, C1
Burghardt, R1
Smith, R1
Wormke, M1
Stewart, J1
Safe, S1
Michael, MS1
Badr, MZ1
Badawi, AF1
Burgermeister, E1
Tencer, L1
Liscovitch, M1
James, SY1
Lin, F1
Kolluri, SK1
Dawson, MI1
Zhang, XK1
Huang, JW1
Shiau, CW1
Yang, YT1
Kulp, SK1
Chen, KF1
Brueggemeier, RW1
Shapiro, CL1
Chen, CS1
Allred, CD1
Kilgore, MW1
Núñez, NP1
Liu, H1
Meadows, GG1
Venkata, NG1
Robinson, JA1
Cabot, PJ1
Davis, B1
Monteith, GR1
Roberts-Thomson, SJ1
Yee, LD1
Sabourin, CL1
Liu, L1
Li, HM1
Smith, PJ1
Seewaldt, V1
Kniss, DA1

Other Studies

13 other studies available for ciglitazone and Breast Neoplasms

ArticleYear
Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells.
    Journal of natural products, 2006, Volume: 69, Issue:4

    Topics: Animals; Apoptosis; Breast Neoplasms; Disulfides; Dose-Response Relationship, Drug; Female; Histone

2006
Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms.
    British journal of pharmacology, 2013, Volume: 169, Issue:5

    Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cells, Culture

2013
Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Cancer letters, 2010, Feb-28, Volume: 288, Issue:2

    Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Butyrates; Cell Line, Tumor

2010
Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.
    Journal of cellular physiology, 2013, Volume: 228, Issue:6

    Topics: Benzophenones; Binding Sites; Breast Neoplasms; Cell Movement; Cell Survival; Dose-Response Relation

2013
Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.
    Cancer research, 2003, Mar-01, Volume: 63, Issue:5

    Topics: Breast Neoplasms; Cell Division; Cyclin D1; Cysteine Endopeptidases; Down-Regulation; Estrogen Recep

2003
Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells.
    International journal of molecular medicine, 2003, Volume: 11, Issue:6

    Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspases; Cell Cycle; Cell Divis

2003
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
    Oncogene, 2003, Jun-19, Volume: 22, Issue:25

    Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveoli

2003
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
    Cancer research, 2003, Jul-01, Volume: 63, Issue:13

    Topics: Apoptosis; Benzoates; Breast Neoplasms; Cell Division; Female; Gene Expression Regulation, Neoplasti

2003
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
    Molecular pharmacology, 2005, Volume: 67, Issue:4

    Topics: Breast Neoplasms; Cell Line, Tumor; Chromans; Cyclin D1; Down-Regulation; Female; Humans; PPAR gamma

2005
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
    Molecular and cellular endocrinology, 2005, May-12, Volume: 235, Issue:1-2

    Topics: Alitretinoin; Anilides; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Female;

2005
PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells.
    Cancer letters, 2006, May-08, Volume: 236, Issue:1

    Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferatio

2006
Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast.
    Toxicology letters, 2006, Jun-01, Volume: 163, Issue:3

    Topics: Breast Neoplasms; Butyrates; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Diethylhexy

2006
Peroxisome proliferator-activated receptor gamma activation in human breast cancer.
    International journal of oncology, 1999, Volume: 15, Issue:5

    Topics: Breast Neoplasms; Cell Division; DNA-Binding Proteins; Female; Genes, Reporter; Humans; Hypoglycemic

1999